Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review.

Ther Adv Med Oncol · 2024 · PMC11653452 · PMID 39697619

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For crizotinib, both PROFILE-1014 and PROFILE-1029 showed a trend toward improved PFS in women (PFS HR 0.45 vs 0.54 in men, and 0.371 vs 0.410 in men, respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.